Lymphoma: all 5,624 studies
Page 45 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.
- HuMax-CD4 in Non-Cutaneous T-Cell LymphomaCompletedNCT00877656Phase 2/3
- Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin LymphomasActive, not recruitingNCT00877214Phase 3
- A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or IntolerableCompletedNCT00876122Phase 1
- SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)TerminatedNCT00871546Phase 2
- Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's LymphomasCompletedNCT00869284Phase 2
- Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)CompletedNCT00864942Phase 1
- Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young PatientsActive, not recruitingNCT00863460Phase 2
- Recalcitrant Pruritus in Cutaneous T-Cell LymphomaTerminatedNCT00863395Phase 1/2
- Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With RituximabStatus unknownNCT00863187Not applicable
- A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid MalignanciesCompletedNCT00861510Phase 1
- Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) TherapyCompletedNCT00859001Phase 2
- Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCLCompletedNCT00854568Phase 3
- L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell LymphomaCompletedNCT00854425Phase 2
- A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00854152Phase 1
- A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00854126Phase 1
- Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) TherapyCompletedNCT00850512Phase 2
- Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)CompletedNCT00850057Phase 1
- Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell LymphomaCompletedNCT00849654Phase 1
- Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) RiskStatus unknownNCT00849355Phase 2
- Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's LymphomaTerminatedNCT00848601Phase 1
- Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin LymphomaTerminatedNCT00848328Phase 2
- Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell LymphomaTerminatedNCT00847223Phase 2
- Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) PatientsStatus unknownNCT00846157Phase 3
- Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive LymphomasCompletedNCT00842595Phase 2
- Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL)CompletedNCT00842114Phase 2
- Treatment of Aggressive Localized LymphomaTerminatedNCT00841945Phase 3
- Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)Status unknownNCT00840385Phase 2
- Temsirolimus for Relapsed/Refractory Hodgkin's LymphomaTerminatedNCT00838955Phase 2
- A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).CompletedNCT00838357Phase 3
- Relapsed and/or Refractory Non-Hodgkin Lymphoma StudyWithdrawnNCT00837174Phase 2
- Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT00836173Phase 2
- Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell LymphomaCompletedNCT00834951Phase 2
- Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell TransplantWithdrawnNCT00833534Phase 2
- Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT00831597Phase 2
- Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to TreatmentWithdrawnNCT00829205Phase 1/2
- A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's LymphomaCompletedNCT00825149Phase 1
- Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced CancerCompletedNCT00823524Phase 1/2
- Samsung Medical Center-Lymphoma Cohort StudyCompletedNCT00822731Not applicable
- Coproporphyrine Isomers and Methotrexate EliminationCompletedNCT00822432
- Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's LymphomaStatus unknownNCT00816959Phase 3
- Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological CancerWithdrawnNCT00816413Phase 1/2
- Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other DiseasesTerminatedNCT00813501
- Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin LymphomaStatus unknownNCT00807196Phase 1/2
- Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological CancerCompletedNCT00806767Phase 2
- Denileukine Diftitox for Relapsed ALCLWithdrawnNCT00801918Phase 2
- First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.CompletedNCT00801281Phase 3
- Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to TreatmentTerminatedNCT00800150Phase 1
- Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
- A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARLCompletedNCT00799136Phase 2
- Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in AdultsStatus unknownNCT00797810Phase 4
- SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's LymphomaCompletedNCT00796731Phase 1
- Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)Status unknownNCT00795613Phase 2
- A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's LymphomaCompletedNCT00794638Phase 1
- Stem Cell Mobilization With Pegfilgrastim in Lymphoma and MyelomaCompletedNCT00794261Phase 2
- A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCTCompletedNCT00791947Phase 2
- Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or VorinostatCompletedNCT00791011Phase 1
- R-CHOP-B Bevacizumab for Diffuse Large B Cell LymphomaTerminatedNCT00788606Phase 2
- Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or LymphomasCompletedNCT00788099Phase 1
- Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00787969Phase 1
- Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)CompletedNCT00786851Phase 2
- Allo-hNHL (FluBuCy)CompletedNCT00785330Phase 2
- High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative PatientsCompletedNCT00784537Phase 2/3
- A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their FamiliesCompletedNCT00782145Phase 3
- Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective StudyStatus unknownNCT00779896Phase 1/2
- Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive LymphomasCompletedNCT00779337Phase 1
- Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving RadioimmunotherapyCompletedNCT00777114Phase 1
- GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT00776802Phase 1/2
- Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's LymphomaTerminatedNCT00775957
- Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular LymphomaStatus unknownNCT00774826Phase 3
- Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple MyelomaCompletedNCT00772811Phase 2
- Zevalin® First Line in Follicular LymphomaStatus unknownNCT00772655Phase 2
- Perceptions of Burden in Patients With Late-Stage Cancer and Their CaregiversWithdrawnNCT00770419
- FAU in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00769288Phase 1
- A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell LymphomasTerminatedNCT00768339Phase 1/2
- Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple MyelomaCompletedNCT00761722Phase 1
- High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell LymphomaCompletedNCT00761384Phase 1/2
- Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United KingdomStatus unknownNCT00757614
- Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)CompletedNCT00754117
- Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical TrialCompletedNCT00750009Phase 3
- Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell LymphomaCompletedNCT00748319Not applicable
- Lymphoma Follow-upCompletedNCT00744120
- Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.TerminatedNCT00742495Phase 1/2
- Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00742144Phase 1
- A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid MalignanciesCompletedNCT00741871Phase 1
- Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).CompletedNCT00741325
- Stem Cell Transplant in Treating Patients With Hematological Cancer or Other DisordersStatus unknownNCT00740467Phase 2
- Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell LymphomaCompletedNCT00740415Phase 2
- HD16 for Early Stage Hodgkin LymphomaStatus unknownNCT00736320Phase 3
- Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00735930Phase 1
- Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00734890Phase 1
- Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSLWithdrawnNCT00734773Early Phase 1
- Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of NetherlandsCompletedNCT00731536
- Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell LymphomaWithdrawnNCT00730652Phase 1
- Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System LymphomaCompletedNCT00727831Phase 1/2
- Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line ChemotherapyTerminatedNCT00727207Phase 2
- Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin LymphomaCompletedNCT00726700Phase 2
- A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple MyelomaCompletedNCT00725634Phase 1
- Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOPStatus unknownNCT00725231Phase 3
- Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantTerminatedNCT00725062Phase 1
- Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular LymphomaStatus unknownNCT00722930Phase 2